

ORIGINAL ARTICLE

Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease

S. M. Belkowski*, J. D. Boot†, M. A. Mascelli‡, Z. Diamant†, L. de Garavilla*, B. Hertzog*, D. Polkovitch*, M. Towers*, A. Batheja* and M. R. D'Andrea*

*Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA, †Centre for Human Drug Research, Leiden, The Netherlands and

‡Centocor, Radnor, PA 19080, USA

Clinical & Experimental Allergy

Summary

Background Secretory leucocyte protease inhibitor (SLPI), which is present in many physiological fluids including saliva, sputum and nasal discharge, is the most effective inhibitor of chymase. Previously, we demonstrated that chymase is able to cleave SLPI and that the cleaved portion, cSLPI, is a biomarker of chymase activity.

Objective We investigated the potential of cSLPI as a biomarker of chymase activity in subjects with allergic rhinitis (AR) and asthmatic airway disease.

Methods Baseline sputum samples were collected from atopic asthmatics and healthy controls (HC). Nasal lavages (NAL) were performed in subjects with AR both at baseline and following a nasal challenge with allergen or placebo. Levels of cSLPI and chymase were determined by Western analysis, and tryptase and α -2 macroglobulin were measured by immunoassay.

Results As compared with HC, asthmatics showed a significant increase in baseline cSLPI/total SLPI ratios and an increase in chymase levels. There was a high correlation of cSLPI/SLPI ratios to chymase levels in normal individuals and untreated asthmatics. In the NAL of patients with AR, as compared with placebo, allergen challenge increased inflammatory biomarkers, including cSLPI/SLPI ratios, chymase levels, tryptase levels and α 2-macroglobulin levels. Correlations were observed between cSLPI/SLPI ratios and chymase levels and cSLPI/SLPI ratios and α 2-macroglobulin levels; no correlation was seen between cSLPI/SLPI ratios and tryptase levels.

Conclusion Our data indicate that cSLPI reflects chymase activity in AR and asthma. Hence, cSLPI may serve as a biomarker for disease activity and for monitoring the efficacy of novel anti-inflammatory treatments in chymase-mediated diseases.

Keywords biomarker, chymase, cSLPI, mast cell, SLPI

Submitted 13 October 2008; revised 20 January 2009; accepted 18 February 2009

Correspondence:

Stanley M Belkowski, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA.

E-mail: sbelkows@its.jnj.com

Introduction

The clinical hallmarks of asthma and allergic rhinitis (AR) are persistent airway inflammation and airway hyperresponsiveness (AHR) [1, 2]. The observation that clinical symptoms and function do not fully reflect the severity of the underlying airway inflammation and AHR [1, 3] has initiated the search for more adequate biomarkers of asthma and AR. Subsequently, the development and validation of non- and semi-invasive sampling techniques, including exhaled nitric oxide, induced sputum and nasal lavage (NAL), helped identify several potential biomarkers of airway inflammation for both clinical

practice and research purposes [4–6]. However, there is still an unmet need to discover sensitive biomarkers from easily obtained samples that are closely linked to the inflammatory cascade that could serve to monitor the progress and treatment of airway diseases.

The mast cell is an important effector cell in the pathophysiology of allergic airway inflammation, AHR and airway remodelling [7–9]. Degranulation of sensitized mast cells by relevant allergen causes the release of histamine and proteases (tryptase and chymase), and *de novo* synthesis of other inflammatory mediators (leukotrienes, prostaglandins, platelet activating factor and bradykinin) [10–12]. On the basis of protease content,

mast cells can be subdivided into at least two phenotypically different subsets: connective tissue mast cells expressing chymase, tryptase and cathepsin G (MC_{TC}), and mucosal mast cells producing tryptase, but no chymase (MC_T) [13]. Although not fully elucidated, chymase originating solely from MC_{TC} cells has recently been implicated in the pathophysiology of airway inflammation, AHR and remodelling of allergic airway disease [9, 14].

The proteinase inhibitors, α 1-antitrypsin, α 1-antichymotrypsin, α 2-macroglobulin and secretory leucocyte protease inhibitor (SLPI), released from neutrophils, macrophages and epithelial cells within the respiratory tract, have been shown to inactivate chymase, providing local protection against allergic stimuli [15–18]. In a previous *in vitro* study, we have shown that SLPI is not only a chymase inhibitor but also a substrate of chymase and that its cleaved product, cSLPI, is a biomarker of chymase activity *in vitro* [19].

Based on these data, we hypothesized that cSLPI may be a biomarker of chymase activity in allergic airway disease *in vivo*. To this end, in two studies originally designed to assess allergic end-points in asthma and AR, we retrospectively measured baseline levels of SLPI and cSLPI in relation to chymase levels. In the first study, we examined SLPI, cSLPI and chymase levels in the sputum of the subjects with allergic asthma in comparison with that of the healthy subjects. In the second study, levels of cSLPI, SLPI, chymase, tryptase and α 2-macroglobulin were measured in NAL of individuals with AR, both under baseline conditions and following nasal allergen challenge.

Methods

Subject groups

Asthmatic subjects study. This part of the study was conducted at the University of Southampton, UK. On one study occasion, hypertonic saline-induced sputum was collected and analysed from 12 participants (6 males/6 females, 18–70 years), subdivided into four study groups with the following characteristics:

1. Healthy non-atopic, non-smoking controls with no chronic respiratory symptoms and no evidence of upper or lower respiratory tract infection in the last 6 weeks [forced expiratory volume in 1 s (FEV₁) > 80% predicted, normal FEV₁/FVC ratio; group 1].
2. Non-smoking subjects with intermittent, atopic asthma (FEV₁ $\geq$ 80% predicted, not on inhaled corticosteroids; group 2).
3. Non-smoking subjects with mild persistent, atopic asthma [FEV₁ $\geq$ 80% predicted; regular use of inhaled corticosteroids: Beclomethasone (Qvar[®]) 100 mcg BD, Fluticasone 100 mcg BD; and the beta agonist Serevent 25 mcg BD; group 3].
4. Non-smoking subjects with moderate–severe persistent atopic asthma [FEV₁ 60–80% predicted; symptomatic despite regular treatment with corticosteroids: Becotide 200mcg QDS; Seretide (1000 mcg fluticasone/200 mcg salmeterol) BD; Seretide (125 mcg fluticasone/25 mcg salmeterol) BD, Prednisolone 40 mg OD; group 4].

All the subjects gave written informed consent, and ethical approval was obtained from the Joint Ethics Committee of Southampton Hospital and General Hospital.

Subjects with allergic rhinitis. NAL specimens were obtained from 20 multi-sensitized, non-smoking patients (10 males/10 females; 19–51 years) with clinically stable AR who were not on maintenance therapy, participating in a clinical study at the Centre for Human Drug Research, Leiden, the Netherlands [20]. All the subjects provided written informed consent and the study was approved by the Ethics Committee of Leiden University Medical Center, Leiden, the Netherlands.

Sputum induction and processing. In the asthma and the healthy subject cohorts ($n = 3$ per subgroup), sputum was induced by hypertonic saline according to the European Respiratory Society (ERS) recommendations [4, 21]. Briefly, following salbutamol pre-treatment, aerosolized hypertonic saline (4.5% NaCl) solution was inhaled at three 5-min intervals by tidal breathing with the nose clipped. In more severe asthmatics, a modified ERS protocol was used starting with normal saline and moving slowly to hypertonic saline only if there was no significant decline in FEV₁. At the end of each 5-min interval, expectorated sputum was collected in a Petri dish and FEV₁ and peak expiratory flow rate were recorded. If FEV₁ declined by $\geq 20\%$ from the post-salbutamol baseline, the procedure was discontinued. Sputum samples were kept on ice and processed within 1 h of collection as described previously [4]. In summary, sputum was teased from the sample using a forceps and collected into a fresh Petri dish, avoiding contamination with saliva and squamous cells. One volume of selected sputum was diluted with four volumes of phosphate-buffered saline (PBS). Four volumes of 6.3 mM dithioerythritol (DTE) were added to one volume of selected sputum, to achieve a final concentration of 5 mM DTE. Subsequently, sputum samples were incubated at room temperature for 30 min on a bench roller. Sputum samples were individually filtered through a 100 μ m nylon mesh cell strainer in order to remove any mucus and debris, and centrifuged at 4 °C, 400 $\times$ g for 10 min. Subsequently, sputum supernatant was transferred to a new 15 mL centrifuge tube and mixed well, samples were aliquotted and stored at –80 °C

pending analysis. For cytopins, an adequate sample of cell suspension was added to a cytopsin tube to achieve a total number of 20–30 000 cells per slide, spun for 5 min, fixed and stained with Hemacolour staining to allow differentiation of cell types. Cytopsin quality was regarded as adequate when squamous cell contamination was <20%.

Nasal lavage. The patients with AR randomly underwent a standardized nasal challenge with either a relevant allergen [house dust mite (HDM), cat or grass allergen; $n = 10$] or its diluent ($n = 10$) in a double-blind, parallel fashion [22]. Selection of the intranasal allergen (HDM, grass pollen or cat dander) was based on the allergen causing the largest weal in the skin prick test, combined with the patient's history of clinical symptoms and the season. The nasal response to allergen was documented by symptom scores previously validated by Lebel [23]. NAL collections were performed according to a modified protocol, sampling the same nostril at pre-challenge and at 20 min post-challenge [22]. NAL samples were collected, kept on ice and processed within 1 h according to a validated protocol [22]. Briefly, samples were centrifuged for 10 min at 400 g; the supernatant was aliquotted and stored at -80°C pending analysis. Frozen samples were shipped to the site of analysis.

Reagents

Recombinant SLPI (rSLPI) was obtained from R&D systems (Minneapolis, MN, USA). Rabbit anti-SLPI antibody was obtained from Alexis (San Diego, CA, USA). Mouse anti-human mast-cell chymase was obtained from Serotec (Raleigh, NC, USA). The secondary antibodies goat anti-mouse and Goat anti-rabbit were obtained from Pierce Biotechnology (Rockford, IL, USA). Tryptase and $\alpha 2$ -macroglobulin were determined according to the manufacturer's directions in the NAL samples with the following assay kits and detection limits: Tryptase by FEIA (Phadia, Uppsala, Sweden), 1 $\mu\text{g/L}$; and $\alpha 2$ -macroglobulin by ELISA (R&D systems), 10 ng/mL.

Sample preparation for Western analysis

During processing, all samples were maintained at 4°C or less to ensure stability of cSLPI and SLPI as determined previously [19]. Ten microlitres of human sputum supernatant or NAL supernatant was diluted to a total volume of 20 μL in a loading buffer containing 50% Nupage LDS sample buffer from Invitrogen (Carlsbad, CA, USA), 30% water and 20% 1 M DTT from Sigma-Aldrich (St Louis,

MO, USA) and was maintained on ice. The samples were boiled for 6 min at 95°C .

Secretory leucocyte protease inhibitor detection by Western analysis

Denatured and reduced sputum supernatant and NAL supernatant samples were applied to a 12% NuPage bis-tris gel from Invitrogen. The samples were electrophoresed and transferred to a PVDF membrane (Pierce Biotechnology). The blots were blocked in 5% milk/PBS-Tween (PBS/0.4% Tween-20) overnight at 4°C . Subsequently, the blots were washed for 10 min and incubated in the primary antibody (goat anti-SLPI at 1:1000) diluted in the blocking solution for 1 h at room temperature. After three washes with PBS-Tween, the blot was incubated for 45 min at room temperature with the secondary antibody [goat anti-rabbit horse raddish peroxidase (HRP)] diluted 1:4000 in blocking solution. The blots were washed six times with PBS-Tween and incubated for 1 min at room temperature with Western Lightning chemiluminescence reagents (Perkin Elmer, Boston, MA, USA) and developed on a Biomax Light Film (Eastman Kodak, Rochester, NY, USA) in the darkroom. Densitometry was performed on each film to determine the relative amount of intact SLPI (~ 15 kDa band) and cSLPI (~ 10 kDa). The data were expressed as a ratio of cSLPI/SLPI for normalization of each sample as done previously [19]. The reliability of this assay was confirmed using mass spectrometry analysis during its development (data not shown).

Chymase Western analysis

Because of the lack of a commercially available chymase ELISA, chymase levels were determined by Western analysis. In brief, denatured and reduced sputum supernatant and NAL supernatant samples were applied to a 12% NuPage bis-tris gel from Invitrogen. The samples were electrophoresed and transferred to a PVDF membrane (Pierce Biotechnology). The blots were blocked in 5% milk/PBS-Tween (PBS/0.4% Tween-20) overnight at 4°C . Subsequently, the blots were washed for 10 min and incubated in the primary antibody (mouse anti-human mast cell chymase at 1:1000) diluted in the blocking solution for 1 h at room temperature. After three washes with PBS-Tween, the blot was incubated for 45 min at room temperature with the secondary antibody (goat anti-mouse HRP) diluted 1:4000 in blocking solution. The blots were washed six times with PBS-Tween and incubated for 1 min at room temperature with Western Lightning chemiluminescence reagents (Perkin Elmer) and developed on a Biomax Light Film (Eastman Kodak) in the darkroom. Densitometry was performed on each film to determine the relative amount of chymase.

Statistical analysis

Data were analysed using a non-parametric Mann–Whitney and Student's *t*-test of endpoint data for the asthma trial. The chymase and α 2-macroglobulin data from the AR trial were log-transformed in order to stabilize variance. The Welch two-sample *t*-test was performed on the slopes of pre-post experimental values. The Pearson correlation coefficient was determined to evaluate the relationship between cSLPI/SLPI ratios and other biomarkers.

Results

General

All sampling methods were well tolerated and no serious adverse events occurred. Analysable sputum could be obtained from all but one asthmatic subject. Because of NAL-sample limitations, chymase levels could only be analysed in nine subjects challenged with placebo and seven in the allergen arm.

Asthmatic subjects

In the sputum samples from asthmatic patients (A), cSLPI/SLPI ratios were determined. One subject's sample from Group 3 could not be analysed due to low volume. As compared with healthy controls (HC) (group 1), cSLPI/SLPI ratios were increased in the sputum of asthmatic subjects (groups 2–4) [0.36 ± 0.02 (HC); 0.45 ± 0.02 (A); $P = 0.04$, Student's *t*-test; $P = 0.049$, non-parametric Mann–Whitney test]. On average, sputum from untreated, atopic asthmatics (group 2) exhibited the highest cSLPI/SLPI ratio (0.50 ± 0.03), while treatment with corticosteroids (groups 3 and 4; $n = 5$) had a lower cSLPI/SLPI ratio (0.41 ± 0.02 ; $P = 0.04$) (Fig. 1). In addition, we measured chymase levels in the same sputum samples and found that the chymase levels followed a similar trend as the cSLPI/SLPI ratios [929.1 ± 301.0 relative units (HC); 1469.4 ± 141.5 relative units (A); $P < 0.17$] (Fig. 2). Despite the low number of samples, a correlation between cSLPI/SLPI ratios and chymase levels in the normal and untreated atopic asthmatics was noted (0.83).

Allergic rhinitis

NALs were collected at baseline and at 20 min post-challenge. As compared with sham challenge (P), intranasal allergen (A) produced an acute allergic response with a mean symptom score [mean $\pm$ SEM: 7.25 ± 0.56 (A); 0.70 ± 0.26 (P); $P = 0.001$] at 10 min post-challenge. In parallel, there was a significant increase in the cSLPI/SLPI ratio following allergen as compared with placebo challenge (Fig. 3). Figure 3a shows the Western analysis




Fig. 1. Sputum cSLPI/SLPI ratios. Example of Western analysis of the lowest and highest cSLPI expression (a). As compared with healthy controls, sputum cSLPI/total SLPI ratios were significantly increased in allergic asthmatics ($P = 0.04$, Student's *t*-test; $P = 0.049$, non-parametric Mann–Whitney test). Corticosteroid use was associated with decreased cSLPI levels ($P = 0.04$, student's *t*-test) (b). cSLPI, cleaved secretory leucocyte protease inhibitor; SLPI, secretory leucocyte protease inhibitor.




Fig. 2. Sputum chymase levels and cSLPI/total SLPI ratios. As compared with healthy controls, in patients with untreated allergic asthma, sputum cSLPI/total SLPI ratios were significantly increased ($P = 0.03$, Student's *t*-test). Chymase levels followed a similar trend with cSLPI/total SLPI ratios in both subject groups. cSLPI, cleaved secretory leucocyte protease inhibitor; SLPI, secretory leucocyte protease inhibitor.

indicating the cSLPI band in the NAL from allergen- (highest level example shown) (left) and placebo-challenged (lowest level example shown) (right) individuals. Using densitometry, the cSLPI/total SLPI ratio was determined for each time-point during both allergen (Fig. 3b) and placebo (Fig. 3c) challenge, respectively. As compared with placebo (0.22 ± 0.02), there was a significant increase in the cSLPI/SLPI ratio in the NAL of allergen-challenged individuals (0.41 ± 0.05 ; $P = 0.007$) at 20 min post-challenge.

Similarly, there was a significant increase in the NAL-chymase levels in the allergen-challenged individuals (1294.85 ± 688.50 relative units; Fig. 4b) as compared with placebo-exposed individuals (706.01 ± 206.11 relative units; $P = 0.038$; Fig. 4c). Changes in the cSLPI/SLPI levels




Fig. 3. Nasal lavages (NAL) cSLPI/SPLI ratio following nasal allergen compared with placebo. Example of Western analysis of NAL from placebo (lowest level cSLPI)- and allergen-challenged allergic rhinitis (AR) – patients (highest level cSLPI) (a). Densitometry analysis of cSLPI/total SPLI ratios in nasal lavage from allergen-challenged (b) and placebo-challenged human AR – patients (c). The Welch *t*-test, $P < 0.007$, allergen-challenged as compared with placebo cSLPI/total SPLI ratio induction from baseline to 20 min post-challenge. Legend refers to patient number. cSLPI, cleaved secretory leucocyte protease inhibitor; SPLI, secretory leucocyte protease inhibitor.




Fig. 4. Nasal lavages (NAL) chymase levels following nasal allergen. Example of Western analysis of NAL from placebo- (lowest level chymase) and allergen-challenged allergic rhinitis (AR) – patients (highest level chymase) (a). Chymase levels (densitometry units) in nasal lavage from allergen-challenged (b) and placebo-challenged (c) human AR – patients. Welch *t*-test, $P < 0.038$, allergen-challenged as compared with placebo from baseline to 20 min post-challenge. Legend refers to patient number. cSLPI, cleaved secretory leucocyte protease inhibitor; SPLI, secretory leucocyte protease inhibitor.

and chymase levels from baseline to 20 min post-allergen challenge were highly correlated ($r = 0.91$) (Fig. 5). If the highest point is removed, the correlation is reduced to $r = 0.69$, which still shows a strong relationship between chymase levels and the cSLPI/SPLI ratio. Using regression analysis with all points, the slope is significant ($P < 0.001$);

with the highest point removed, the trend is still significant ($P < 0.006$).

In parallel to the increases in cSLPI and chymase, there was a significant increase in the NAL levels of $\alpha 2$ -macroglobulin (a protease inhibitor) (6630 ± 4240 ng/mL (A) vs. 50.75 ± 28.76 ng/mL (P); $P = 0.00035$) (Figs 6a and

b) at 20 min post-challenge. Similarly, tryptase (a mast cell protease) also increased in the allergen-challenged group (4.3 ± 2.01 ng/mL) as compared with placebo (undetectable levels; $P < 0.056$) (Figs 7a and b). A correlation analysis of cSLPI/SLPI ratios compared with each of the other biomarkers measured in this study shows a much stronger correlation between NAL cSLPI/SLPI ratios and chymase levels (0.91) and cSLPI/SLPI and $\alpha 2$ -macroglobulin levels (0.41) as compared with cSLPI/SLPI ratios and tryptase levels (0.07) (Figs 3–7).

Discussion

The function of SLPI is to protect tissues against the harmful effects of environmental irritants through its anti-inflammatory, anti-protease and anti-microbial properties [18]. Within the respiratory tract, SLPI is produced by a variety of cells including neutrophils, macrophages and epithelial cells [15]. SLPI is cleaved by

chymase at a specific site and the level of this cleavage product, cSLPI, is indicative of chymase activity [19]. Here, we report increased baseline cSLPI levels in the sputum and the NAL of the subjects with untreated allergic asthma and AR, respectively, with a further increase following a nasal-allergen challenge in the AR group. These findings are suggestive of an enhanced chymase activity in allergic airway disease *in vivo* and hence extend our previous *in vitro* observations.

Based on *in vitro* data of our previous publication [19], cSLPI can be used as a measure of chymase activity in biological samples. We observed, that out of a panel of mast cell proteases consisting of proteinase 3, elastase, tryptase, cathepsin G, chymotrypsin and chymase, only chymase is able to cleave SLPI [19]. SLPI acts as a first line of inhibition but is also cleaved by the chymase. This allows us to see a record of chymase activity before $\alpha 2$ -macroglobulin and other inhibitors inhibit it irreversibly.

In the present study, we measured cSLPI levels in airway samples from patients with allergic airway disease. Increased cSLPI levels were demonstrated in the sputum of patients with untreated allergic asthma, while use of corticosteroids was associated with reduced cSLPI levels. However, this finding is somewhat difficult to interpret because these individuals were also more severe asthmatics. Unfortunately, we are unable to obtain specimens from severe asthmatics who are not receiving either oral or inhaled corticosteroids. cSLPI was also increased in NAL of subjects with AR at 20 min following an intranasal allergen challenge, which elicited an early nasal response. In accordance with previous observations [19], cSLPI appeared to be closely correlated to chymase levels in both asthma (0.83) and AR (0.91). Taken together, these data suggest that cSLPI may act as a biomarker of chymase activity in allergic airway disease *in vivo*.

Apart from cSLPI and chymase, other markers of (mast cell related) airway inflammation were increased,




Fig. 5. Correlation of cSLPI/SLPI and chymase levels in allergic rhinitis. Changes in nasal lavages cSLPI/SLPI levels and chymase levels from baseline to 20 min post-allergen challenge are highly correlated ($r = 0.91$). cSLPI, cleaved secretory leucocyte protease inhibitor; SLPI, secretory leucocyte protease inhibitor.




Fig. 6. Nasal lavages (NAL) $\alpha 2$ -macroglobulin levels following nasal allergen. $\alpha 2$ -macroglobulin levels are elevated in NAL following nasal allergen challenge allergic rhinitis – patients (a) vs. placebo challenge (b). The Welch *t*-test, $P = 0.00035$, allergen-challenged as compared with placebo from baseline to 20 min post-challenge. Legend refers to patient number. cSLPI, cleaved secretory leucocyte protease inhibitor; SLPI, secretory leucocyte protease inhibitor.




Fig. 7. Nasal lavages (NAL) tryptase levels following nasal allergen. Tryptase levels are detectable only in NAL following allergen challenge (a) while none is detected following placebo-challenged allergic rhinitis – patients (b). Student's *t*-test, $P = 0.056$, allergen-challenged as compared with placebo from baseline to 20 min post-challenge. Legend refers to patient number. cSLPI, cleaved secretory leucocyte protease inhibitor; SLPI, secretory leucocyte protease inhibitor.

including tryptase, a marker of mast cell activity [24], and $\alpha 2$ -macroglobulin, a key inhibitor of chymase [25] in AR. Following a nasal allergen challenge, all these biomarkers were further increased. $\alpha 2$ -macroglobulin levels correlated well with the increased levels of cSLPI (0.41). This was expected, as $\alpha 2$ -macroglobulin is an inhibitor of chymase [25], and had a high correlation with chymase levels as well (0.62). We observed an apparent 10-fold greater amount of tryptase as compared with chymase and cSLPI in the NAL following allergen challenge. We attribute this to the relatively greater amounts of tryptase stored in mast cells, up to 25% of cellular protein [26], as compared with chymase. Moreover, tryptase can originate from both MC_{TC} and MC_T cells, whereas chymase originates only from MC_{TC} cells, and the relative degranulation of each of these mast cell types to the allergic response varies [27]. In addition, some of the disparity in relative changes in chymase and tryptase could be related to the differences in the methods of measurement – highly quantitative ELISA was used for tryptase and $\alpha 2$ -macroglobulin, while a qualitative Western was used for chymase and cSLPI. Consequently, it is not surprising to note that the increase in the tryptase levels, although indicative of mast cell activity, did not correlate with cSLPI/SLPI ratios (0.07), confirming that cleavage of SLPI is not based on the presence of tryptase as observed in our previous study [19]. Interestingly, one-third of the subjects in the present nasal challenge study did not show an increase in NAL tryptase levels. It appears that tryptase is not necessarily elevated in all atopic individuals with airway disease. Bettiol et al showed that only 18% of asthmatics exhibited elevated tryptase levels [28].

Until now, no direct measure was available for chymase activity in biological fluids due to its short half-life, mainly caused by the high content of chymase inhibitors [25, 29]. The advantages of the use of cSLPI as a biomarker of chymase activity are that SLPI cleavage is easily

detectable in readily accessible human samples of saliva, sputum and NAL. Additionally, known chymase inhibitors will inhibit the level of SLPI cleavage [19]. Furthermore, disease states such as AR and asthma result in higher amounts of cleaved SLPI. Taken together, the data show that detection of these unique SLPI cleavage products can act as novel biomarkers of chymase activity and chymase-mediated disease.

However, we do acknowledge several shortcomings of this particular study that begins with the sample size. Despite obvious relationships between the inflammatory markers, low patient numbers make it difficult to achieve adequate correlation values. Furthermore, in this population some asthma patients were using (inhaled) corticosteroids, whereas others were untreated. Even though significantly lower levels were detected in those on corticosteroids, the effect of these drugs on cSLPI levels needs to be prospectively evaluated in a well-powered, placebo-controlled study.

In conclusion, our data show that cSLPI may be an *in vivo* biomarker of chymase activity in allergic airway disease. Our findings need confirmation from larger prospective trials in patients with well-defined disease characteristics and various treatments.

Acknowledgement

The authors thank Dr. Mariusz Lubomirski for the statistical analysis.

References

- 1 Global Strategy for Asthma Management and Prevention – 2008. <http://www.ginasthma.com/Guidelineitem.asp?l1=2&l2=1&intId=1561>.

- 2 Bousquet PJ, Combescure C, Neukirch F *et al*. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. *Allergy* 2007; **62**:367–72.
- 3 Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. *J Allergy Clin Immunol* 1999; **103** (Part 1):232–7.
- 4 Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. *Eur Respir J* 2002; **37** (Suppl.):1s–2s.
- 5 Baraldi E, de Jongste JC. Measurement of exhaled nitric oxide in children, 2001. *Eur Respir J* 2002; **20**:223–37.
- 6 Boot JD, Panzner P, Diamant Z. A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma. *Pulm Pharmacol Ther* 2007; **20**:201–19.
- 7 Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 2002; **346**:1699–705.
- 8 KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. *J Allergy Clin Immunol* 2000; **106**:677–86.
- 9 Zanini A, Chetta A, Saetta M *et al*. Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma. *J Allergy Clin Immunol* 2007; **120**:329–33.
- 10 Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001; **108** (5 Suppl.):S147–334.
- 11 Kay AB. Allergy and allergic diseases. Second of two parts. *N Engl J Med* 2001; **344**:109–13.
- 12 Kay AB. Allergy and allergic diseases. First of two parts. *N Engl J Med* 2001; **344**:30–7.
- 13 Al Suleimani YM, Walker MJ. Allergic rhinitis and its pharmacology. *Pharmacol Ther* 2007; **114**:233–60.
- 14 Westin U, Lundberg E, Wihl JA, Ohlsson K. The effect of immediate-hypersensitivity reactions on the level of SLPI, granulocyte elastase, alpha1-antitrypsin, and albumin in nasal secretions, by the method of unilateral antigen challenge. *Allergy* 1999; **54**:857–64.
- 15 Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. *Infect Immun* 2005; **73**:1271–4.
- 16 Walter M, Plotnick M, Schechter NM. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. *Arch Biochem Biophys* 1996; **327**:81–8.
- 17 Westin U, Lundberg E, Ohlsson K. IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release. *Mediators Inflamm* 1998; **7**:217–20.
- 18 Weldon S, McGarry N, Taggart CC, McElvaney NG. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. *Biochem Soc Trans* 2007; **35** (Part 2):273–6.
- 19 Belkowski SM, Masucci J, Mahan A *et al*. Cleaved SLPI, a novel biomarker of chymase activity. *Biol Chem* 2008; **389**:1219–24.
- 20 Boot JD, de Kam ML, Mascelli MA *et al*. Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis. *Allergy* 2007; **62**:378–84.
- 21 Paggiaro PL, Chanez P, Holz O *et al*. Sputum induction. *Eur Respir J* 2002; **37** (Suppl.):3s–8s.
- 22 de Graaf-in't Veld C, Garrelds IM, van Toorenenbergen AW, Gerth van Wijk R. Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response. *Thorax* 1997; **52**:143–8.
- 23 Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. *J Allergy Clin Immunol* 1988; **82** (Part 1): 869–77.
- 24 Jacobi HH, Skov PS, Poulsen LK, Malling HJ, Mygind N. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. *J Allergy Clin Immunol* 1999; **103** (Part 1):768–72.
- 25 Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by alpha(2)-macroglobulin. *Arch Biochem Biophys* 1999; **368**:276–84.
- 26 Caughey GH. Of mites and men: trypsin-like proteases in the lungs. *Am J Respir Cell Mol Biol* 1997; **16**:621–8.
- 27 Bradding P, Okayama Y, Howarth PH, Church MK, Holgate ST. Heterogeneity of human mast cells based on cytokine content. *J Immunol* 1995; **155**:297–307.
- 28 Bettiol J, Radermecker M, Sele J, Henquet M, Cataldo D, Louis R. Airway mast-cell activation in asthmatics is associated with selective sputum eosinophilia. *Allergy* 1999; **54**:1188–93.
- 29 Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. *J Biol Chem* 1989; **264**:21308–15.